# AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer

> **NCT02513563** · PHASE2 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 42 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **DRUG:** AZD1775

## Key facts

- **NCT ID:** NCT02513563
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-13
- **Primary completion:** 2022-11-27
- **Final completion:** 2023-11-28
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2026-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02513563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02513563, "AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02513563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*